Date:Jul 22, 202	1
Your Name:	_Jian Lu
Manuscript Title:	_ Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus
Statement from an	International Expert Panel of ISMIO
Manuscript number	(if known): HBSN-21-260

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time from a most	26
2	Consider the second second second	Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	Nava	
6	Payment for expert	None	
	testimony		
_	Cooperat for other diam	Name	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests		

Dr. Jl reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22, 2021_	<u> </u>
Your Name:	Ming Zhao
Manuscript Title:(Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus
Statement from an In	ternational Expert Panel of ISMIO
Manuscript number (i	f known): HBSN-21-260

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
	5 ,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. MZ reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22,	2021
Your Name:	Yasuaki Arai
Manuscript Title	e: Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus
Statement from	an International Expert Panel of ISMIO
Manuscript num	ber (if known): HBSN-21-260

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None	

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Cupport for attending	None	
/	Support for attending meetings and/or travel	None	
	ineetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Porticipation on a Data	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	12 Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. YA reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22, 2021				
Your Name:	Bin-Yan Zhong			
Manuscript Title:	Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus			
Statement from an Ir	ternational Expert Panel of ISMIO			
Manuscript number	if known): HBSN-21-260			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Cuppert for attending	None	
/	Support for attending meetings and/or travel	None	
	ineetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Porticipation on a Data	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	12 Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. BYZ reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22, 2021				
Your Name:	Hai-Dong Zhu			
Manuscript Title:	Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus			
Statement from an I	nternational Expert Panel of ISMIO			
Manuscript number	(if known): HBSN-21-260			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Cupport for attending	None	
/	Support for attending meetings and/or travel	None	
	ineetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Porticipation on a Data	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	12 Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. HZ reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22, 2021				
Your Name: Xiao-Long Qi				
Manuscript Title: Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensu				
Statement from an International Expert Panel of ISMIO				
Manuscript number (if known): HBSN-21-260				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Cupport for attending	None	
/	Support for attending meetings and/or travel	None	
	ineetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Porticipation on a Data	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	12 Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. XQ reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22, 2021				
Your Name: Thierry	de Baere			
Manuscript Title: Clinical	Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensu			
Statement from an Internatio	nal Expert Panel of ISMIO			
Manuscript number (if knowi	ı): HBSN-21-260			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	- 19	
	,		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
	Static of Static options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. TDB reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22, 2021				
Your Name:	_Uei Pua			
Manuscript Title:	Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus			
Statement from an I	nternational Expert Panel of ISMIO			
Manuscript number	(if known): HBSN-21-260			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	26 months
2	Grants or contracts from	None	
	any entity (if not indicated	INOTIC	

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Cupport for attending	None	
/	Support for attending meetings and/or travel	None	
	ineetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Porticipation on a Data	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	·		
12	12 Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. UP reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22, 2021					
Your Name:	Hyun Ki Yoon				
Manuscript Title:	Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus				
Statement from an li	nternational Expert Panel of ISMIO				
Manuscript number (if known): HBSN-21-260					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Name	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	INOTIC	
	meetings and, or traver		
8	Patents planned, issued or	None	
٥	pending	Notie	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
42	services	N.	
13	Other financial or non-financial interests	None	

Dr. HKY reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22, 2021					
Your Name:	David C Madoff				
Manuscript Title:	Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus				
Statement from an In	ternational Expert Panel of ISMIO				
Manuscript number (f known): HBSN-21-260				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None	

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Nama	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
/	meetings and/or travel	INOTIE	
	meetings and/or traver		
	5		
8	Patents planned, issued or pending	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. DCM reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement:

Date:Jul 22, 202	21
Your Name:	_ Gao-Jun Teng
Manuscript Title:	_ Clinical Practice of Transarterial Chemoembolization for Hepatocellular Carcinoma: Consensus
Statement from an	International Expert Panel of ISMIO
Manuscript numbe	r (if known): HBSN-21-260

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The study was supported by Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).	The funding sources had no role in the writing of the report, or decision to submit the paper for publication.
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Nama	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
/	meetings and/or travel	INOTIE	
	meetings and/or traver		
8	Patents planned, issued or pending	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Dr. GT reports grants from Jiangsu Provincial Special Program of Medical Science (BL2013029), National Natural Science Foundation of China (81827805), and National Key Research and Development Program (2018YFA0704100).

Please place an "X" next to the following statement to indicate your agreement: